CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
OC-01 (varenicline) nasal spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03688802
NCT03688802Phase 2Completed
CompareCT.gov

A Single-Center, Randomized, Controlled, Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study)

Oyster Point Pharma, Inc.·interventional·Posted Sep 28, 2018·Updated Dec 29, 2021

In Brief

A Phase 2 clinical trial evaluating OC-01 (varenicline) nasal spray and Placebo (vehicle control) nasal spray for Dry Eye Disease. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 28, 2018
Enrollment StartSep 25, 2018
Primary CompletionSep 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.8 years ago

Interventions

OC-01 (varenicline) nasal spraydrug

OC-01 (varenicline) nasal spray

Placebo (vehicle control) nasal spraydrug

Placebo